Thomas Miller
Family Medicine · Angola, INNPI 1326048802
Payments from drug & device makers
Across 96 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$289
- Novo Nordisk$204
- Axsome Therapeutics, Inc.$143
- Phathom Pharmaceuticals, Inc.$133
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$105
- Pfizer$90
- plus $800 from 22 others
What the payments were for
- Food & beverage$1,765100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $289 |
| Novo Nordisk | 12 | $204 |
| Axsome Therapeutics, Inc. | 3 | $143 |
| Phathom Pharmaceuticals, Inc. | 2 | $133 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $105 |
| Pfizer | 5 | $90 |
| Otsuka America Pharmaceutical, Inc. | 1 | $89 |
| Boehringer Ingelheim | 4 | $74 |
| Astellas Pharma US Inc | 3 | $65 |
| Exact Sciences | 4 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $58 |
| Amgen | 4 | $56 |
| Johnson & Johnson | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $44 |
| AstraZeneca | 2 | $39 |
| Lilly USA, LLC | 3 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Abbott | 2 | $30 |
| GSK | 2 | $25 |
| Dexcom, Inc. | 1 | $20 |
| Dermira, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Novartis | 1 | $13 |
| Merck | 1 | $12 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Therapeuticsmd, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,765 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 74 | $132,287 |
| OzempicSemaglutide | 83 | $102,469 |
| JanuviaSitagliptin Phosphate | 51 | $55,811 |
| FarxigaDapagliflozin Propanediol | 32 | $49,767 |
| JardianceEmpagliflozin | 28 | $48,319 |
| EliquisApixaban | 21 | $35,907 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $32,239 |
| XareltoRivaroxaban | 16 | $20,818 |
| MounjaroTirzepatide | 11 | $19,484 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $13,638 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $11,096 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $8,272 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $6,116 |
| Sucralfate | 13 | $4,399 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $3,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $36 | $151,77085 claims |
| Novo NordiskOzempic | $204 | $102,46983 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $39 | $65,98858 claims |
| MerckJanuvia | $12 | $55,81151 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $25 | $49,45177 claims |
| Boehringer IngelheimJardiance | $74 | $48,31928 claims |
| PfizerEliquis | $90 | $35,90721 claims |
| Johnson & JohnsonXarelto | $56 | $20,81816 claims |
| AbbVieSynthroid | $289 | $1,53325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Angola
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.